Roche, Herzog&De MeuronGenentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.
Tag Archive for: M&A
H.Lundbeck A/SLundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.
Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypsos US$250m upfront upon closing plus of up to US$175.
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the companys NSCLC candidate.
C